“Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Peripheral T-Cell Lymphomas Market.
The Peripheral T-Cell Lymphomas Pipeline report embraces in-depth commercial, regulatory, and Peripheral T-Cell Lymphomas clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Peripheral T-Cell Lymphomas drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Peripheral T-Cell Lymphomas treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Peripheral T-Cell Lymphomas therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Peripheral T-Cell Lymphomas companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Peripheral T-Cell Lymphomas drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Peripheral T-Cell Lymphomas therapeutic market.
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Landscape
Most PTCL subtypes are aggressive lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal NK cell/T-cell lymphoma with 5-year survivals of less than 30% except for anaplastic lymphoma kinase-positive ALCL. Most PTCLs are diagnosed by taking a small sample (a “biopsy”) of an enlarged lymph node and then examining the cells under a microscope
The existing treatment includes nonsurgical and surgical protocols, wherein, the nonsurgical protocol includes physical therapy and medications. In contrast, the surgical protocols include different surgical procedures such as discectomy or microdiscectomy, laminectomy or laminotomy. Gene expression and molecular profiling have demonstrated significant heterogeneity amongst cases of PTCL and have led to the identification of potential therapeutic targets such as platelet-derived growth factor-alpha and NF-kappaB.
The Peripheral T-Cell Lymphomas therapeutics market is expected to grow due to factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the upcoming products such as AFM-13, Nanatinostat, etc. are anticipated to expand the market growth.
There are approx. 40+ key companies developing therapies for Peripheral T-Cell Lymphomas (PTCL). Currently, some of the leading companies such as HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma Co., Ltd., Solasia Pharma K.K., CerRx, Inc., and Seattle Genetics have their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the mid to advanced stage of clinical development.
Peripheral T-Cell Lymphomas Companies Actively Working in the Therapeutic Market Include:
-
Acrotech Biopharma LLC
-
HUYA Bioscience International
-
Seattle Genetics, Inc.
-
Akeso Pharmaceuticals, Inc.
-
Shandong New Time Pharmaceutical Co., LTD
-
Verastem, Inc.
-
Genor Biopharma Co., Ltd.
-
CerRx, Inc.
-
Shanghai YingLi Pharmaceutical Co. Ltd.
-
Dizal Pharmaceuticals
-
Kura Oncology, Inc.
And Many Others
Emerging and Marketed Peripheral T-Cell Lymphomas (PTCL) Drugs Covered in the Report Include:
-
HBI-8000: HUYA Bioscience International
-
Valganciclovir: Viracta Therapeutics
-
Golidocitinib: Dizal Pharmaceuticals
-
Valemetostat Tosylate: Daiichi Sankyo
-
AFM 13: Affimed
-
COPIKTRA: Secura Bio
-
Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals
-
Tislelizumab: BeiGene
-
Zarnestra (Tipifarnib): Kura Oncology
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Peripheral T-Cell Lymphomas Companies Working in the Market @
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight
Analysis of Emerging Peripheral T-Cell Lymphomas (PTCL) Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Peripheral T-Cell Lymphomas (PTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Subcutaneous
-
Intravenous
-
Oral
-
Intramuscular
-
Intra-tumoral
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal antibodies
-
Immunoglobulins
-
Small molecules
-
Pyrimidines
-
Proteins and Peptides
Learn How the Peripheral T-Cell Lymphomas Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphomas Treatment Patterns
4. Peripheral T-Cell Lymphomas – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Peripheral T-Cell Lymphomas Late Stage Products (Phase-III)
7. Peripheral T-Cell Lymphomas Mid-Stage Products (Phase-II)
8. Peripheral T-Cell Lymphomas Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Peripheral T-Cell Lymphomas Discontinued Products
13. Peripheral T-Cell Lymphomas Product Profiles
14. Major Peripheral T-Cell Lymphomas Companies in the Market
15. Key Products in the Peripheral T-Cell Lymphomas Therapeutics Segment
16. Dormant and Discontinued Products
17. Peripheral T-Cell Lymphomas Unmet Needs
18. Peripheral T-Cell Lymphomas Future Perspectives
19. Peripheral T-Cell Lymphomas Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Seborrhea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Seborrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Seborrhea market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research